First and only PARP inhibitor to improve overall survival in early breast cancer
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Aims to become India’s leading cancer testing company
Venus Remedies secures marketing authorization in Philippines
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
For people with relapsed or refractory diffuse large B-cell lymphoma
Reaffirms Lupin’s commitment to sustainable resource management
Subscribe To Our Newsletter & Stay Updated
